Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

reacting like a CCR5-Delta 32 patient Yes that

Message Board Public Reply | Private Reply | Keep | Replies (2)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154721
(Total Views: 682)
Posted On: 11/01/2019 8:34:29 PM
Avatar
Posted By: trding
Re: TechGuru #10411
Quote:
reacting like a CCR5-Delta 32 patient



Yes that is what Dr. Sacha said in the cc, leronlimab turns cells into delta-32. And they I believe they used that to cure HIV in monkeys. I don't believe there are ccr5 delta 32 donors like with humans, so they used leronlimab to simulate a ccr5 delta 32 donor and it worked from what I gather.

When that gets published it will be big news imo. NP said end of year but this week said end of year or 1st quarter. I'm not sure if this is the CROI, if it is, it will not be released until March 10th.

There is one big difference though, it blocks hiv, binding to similar location, being competitive with hiv and rantes(ccl5). But it allows ccl3 and ccl4 to continue to bind. ccr5 delta 32 people have a couple issues, with some viruses like the flu, they have a higher death rate. But the paper I posted earlier, didn't have the same issue with ccr5 antagonists, shown with mice studies as with ccr5 deficient mice, which had the same flu issue. The issue was without ccr5 for ccl3 and ccl4 to bind, they bound to other receptors which caused the issue. So leronlimab, I believe will give the best of both worlds blocking rantes, but allowing ccl3 and ccl4 to continue working, which is why the safety data is much better that other ccr5 antagonists. This ccl5, rantes, is what some cancers use to recruit t-cells, a layer of protection around them. So blocking that is one reason this should work well with cancer, removing that layer of protection.


(3)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us